Interstitial lung disease/pneumonitis with Votrient
Interstitial lung disease/pneumonitis has been added to the summary of product characteristics for Votrient (pazopanib; Novartis) as a rare adverse event.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068728
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com